Filtered By:
Condition: Stroke
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 81118 results found since Jan 2013.
Claret Medical raises $11m
Claret Medical has raised $11.2 million in a new round of equity financing, according to an SEC filing posted this week.
Money in the round came from 34 unnamed investors, according to the SEC filing, with the 1st sale dated on June 22.
Claret Medical is still looking to raise an additional $6.5 million in the round, according to the SEC filing. The company has not yet stated how it intends to use funds raised in the round.
The Santa Rosa, Calif.-based company produces the Sentinel embolic protection device designed to trap blood clots and prevent stroke during heart valve replacement procedures.
The Sentinel device uses a...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Claret Medical Inc. Source Type: news
Excellance Finishes New Mobile Stroke Unit Packed With All of the Latest Medical Technology to Diagnose and Treat Strokes
Excellance has delivered a new Mobile Stroke Unit (MSU) to Indiana University Health. These units are best-in-class for saving lives, preserving brain function, reducing post-hospitalization costs, and cutting alarm-to-therapy decision time by half.
Indiana University Health Neurology and Neurosurgery features the latest and greatest in the world of healthcare, adding another tool to their stewardship in the world of neurological care and live-saving treatments. The latest in medical technology, the MSU features an onboard mobile CT scanner, lab, and telemedicine unit, allowing the doctor to interface with the unit and ...
Source: JEMS: Journal of Emergency Medical Services News - July 30, 2017 Category: Emergency Medicine Authors: Excellance Tags: Industry News Operations Source Type: news
Resuscitation Ventilation with CCSV – Experience the Innovation at ERC Congress in Freiburg
(Hamburg) – Medical device manufacturer WEINMANN Emergency has developed a ventilation mode specially designed for resuscitation, Chest Compression Synchronized Ventilation (CCSV). CCSV applies a pressure-controlled mechanical breath synchronously with each chest compression, avoiding the disadvantages of conventional ventilation forms during resuscitation, while simultaneously improving gas exchange and hemodynamics. For the first time, mechanical breaths with a regulated peak pressure are delivered synchronously with chest compressions – a revolution that could replace volume-controlled ventilation as the gold standa...
Source: JEMS: Journal of Emergency Medical Services News - September 8, 2017 Category: Emergency Medicine Authors: Weinmann Medical Technology Tags: Patient Care Industry News Source Type: news
PeaceHealth Southwest Medical Center Sets New Precedent for Emergency Care Using Mobile Technology
BOZEMAN, MT -- Stroke is a leading cause of disability and death in the U.S., with close to 800,000 cases each year. The outcome can be devastating, and every delay in care impacts a stroke survivor’s chance at a full recovery. To minimize those delays and make emergency communication more efficient, PeaceHealth Southwest Medical Center in Vancouver, Washington, has partnered with several local EMS services to begin using the healthcare communication platform, Pulsara. PeaceHealth Southwest is the first hospital on the west coast to use Pulsara, and the first in the nation to use the company's Prehospital Alerting Packag...
Source: JEMS: Journal of Emergency Medical Services News - September 18, 2017 Category: Emergency Medicine Authors: Pulsara Tags: Documentation & Patient Care Reporting Industry News Source Type: news
Claret Medical touts Sentinel data in TAVR study
Claret Medical today released results from a study of its Sentinel cerebral protection system, touting reduced early occurrence of stroke associated with transcatheter aortic valve replacement procedures and lowered mortality rates.
The study of the device was recently published in the Journal of the American College of Cardiology: Cardiovascular Interventions, the Santa Rosa, Calif.-based company said.
The Sentinel embolic protection device is designed to trap blood clots and prevent stroke during heart valve replacement procedures, which Claret Medical touts as the 1st and only FDA-cleared device to do so.
“In pat...
Source: Mass Device - September 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Neurological Claret Medical Inc. Source Type: news
Claret Medical raises $21m
Claret Medical has raised $21.2 million in a new round of equity financing, according to an SEC filing posted this week.
The Santa Rosa, Calif.-based company is not seeking to raise any more funds in the round and has not yet stated how it plans to spend the funds it raised.
Money in the round came from 35 anonymous investors, according to the SEC filing, with the 1st sale noted on June 22.
Earlier this week, Claret Medical released results from a study of its Sentinel cerebral protection system, touting reduced early occurrence of stroke associated with transcatheter aortic valve replacement procedures and lowered mortali...
Source: Mass Device - October 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Claret Medical Inc. Source Type: news
Contego Medical launches Neuroguard IEP trial
Contego Medical said today it launched the Performance I trial of its Neuroguard IEP 3-in-1 carotid stent and post-dilation balloon system with integrated embolic protection designed to treat carotid artery stenosis.
The first patient in the trial has already been enrolled and treated at Skopje, Macedonia’s University Clinic of Cardiology by Dr. Saško Kedev, the Raleigh, N.C.-based company said.
“We are pleased to initiate this trial evaluating the Neuroguard IEP System, the first of its kind for carotid stenting. Protection from stroke is key during carotid artery interventions. This 3-in-1 system includes a ...
Source: Mass Device - March 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Contego Medical Source Type: news
Five-Year Outcomes of Successful Percutaneous Coronary Intervention with Drug-Eluting Stents versus Medical Therapy for Chronic Total Occlusions.
CONCLUSION: In this study, successful CTO PCI with DESs was associated with a higher risk of repeat PCI for the target vessel, but showed a reduced incidence of death or MI.
PMID: 29869458 [PubMed - in process]
Source: Yonsei Medical Journal - June 6, 2018 Category: Universities & Medical Training Authors: Rha SW, Choi BG, Baek MJ, Ryu YG, Li H, Choi SY, Byun JK, Mashaly A, Park Y, Jang WY, Kim W, Choi JY, Park EJ, Na JO, Choi CU, Lim HE, Kim EJ, Park CG, Seo HS, Oh DJ Tags: Yonsei Med J Source Type: research
Silk Road Medical touts TCAR study data
Silk Road Medical today released results from studies of its transcarotid artery revascularization procedure, touting favorable outcomes in treating patients with carotid artery disease.
Data from the studies were presented at the Society for Vascular Surgery 2018 Vascular Annual Meeting in Boston.
The transcarotid artery revascularization procedure uses the Sunnyvale, Calif.-based company’s Enroute transcarotid stent and neuroprotection system, and is intended to treat blockages in the carotid artery that are at risk of causing a stroke.
Results from a two-year study which compared outcomes from 1,182 patients who r...
Source: Mass Device - June 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Silk Road Medical Inc. Source Type: news
Boston Scientific puts $270m on the table for Claret Medical
Boston Scientific (NYSE:BSX) said today that it agreed to pay as much as $270 million to acquire Claret and its Sentinel device.
Marlborough, Mass.-based Boston Scientific said the deal involves an ip-front cash payment of $220 million and another $50 million pegged to a reimbursement milestone. Claret’s Sentinel device is designed to trap and remove debris dislodged during transcatheter aortic valve replacements to prevent stroke and other neurological damage.
After landing CE Mark approval in the European Union in 2014, Santa Rosa, Calif.-based Claret won de novo clearance from the FDA last year for the Sentinel d...
Source: Mass Device - July 20, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Replacement Heart Valves Wall Street Beat Boston Scientific Claret Medical Inc. Source Type: news
NIH Extends URMC ’s Role in Network to Advance Neurological Care
National Institute of Neurological Disorders and Stroke has extended the University of Rochester Medical Center ’s membership in the Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, which was created to accelerate clinical research involving new treatments for neurological disorders. The $1.5 million grant to URMC will provide patients in the region access to cutting-edge experimental t herapies and continue the Medical Center’s key role in helping bring new drugs to market.
Source: University of Rochester Medical Center Press Releases - July 26, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
FDA clears Contego Medical ’ s Paladin carotid balloon
Contego Medical said today that it won 510(k) clearance from the FDA for its Paladin carotid balloon with embolic protection.
Raleigh, N.C.-based Contego said the Paladin device consists of an angioplasty balloon and a 40-micron filter for carotid stenting procedures. It won CE Mark approval in 2015 in the European Union, where it launched the following January.
A post-market surveillance study of 106 patients showed a 0.9% risk of death, stroke and myocardial infarction at 30 days and zero procedural strokes, the company said.
“We are thrilled to have achieved this milestone for the first of several devices Conteg...
Source: Mass Device - September 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Food & Drug Administration (FDA) Contego Medical Source Type: news
Conformal Medical raises $9m Series B for anti-stroke cardiac implant
Conformal Medical said today that it raised $9 million in a Series B round for the anti-stroke cardiac implant it’s developing.
Nashua, N.H.-based Conformal is working on a left atrial appendage seal to prevent stroke in atrial fibrillation patients. It’s designed to adapt to the each patient’s individual physiology, to be easier to implant with less imaging and without general anesthesia.
The funding round was led by Catalyst Health Ventures and included “a supportive group of Series A investors,” Conformal said.
“This financing will allow us to validate our novel sealing technology ...
Source: Mass Device - December 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Implants Featured Funding Roundup Wall Street Beat Conformal Medical Source Type: news
Silk Road Medical sets downsized range for IPO
Silk Road Medical yesterday set the range on its forthcoming initial public offering, which would fetch $75 million at the midpoint.
The Sunnyvale, Calif.-based company’s Enroute transcarotid stent and neuroprotection system is designed to treat carotid artery blockages before they cause a stroke. When it registered the IPO earlier this month, Silk Road said it could fetch as much as $86 million. But yesterday the company said it plans to float nearly 4.7 million shares at $15 to $17 apiece, for gross proceeds of $70.5 million to $79.9 million.
Silk Road has said it plans to use the cash to expand its sales force and ope...
Source: Mass Device - March 26, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Funding Roundup Wall Street Beat Silk Road Medical Inc. Source Type: news
UPDATE: Silk Road Medical prices $120m IPO
Updated to include comment from CEO Erica Rogers
Silk Road Medical late yesterday priced its initial public offering, looking to raise approximately $120 million.
The Sunnyvale, Calif.-based company said it plans to float 6 million shares of its common stock at a price of $20 per share. The offering also includes a 30-day underwriters option to purchase an additional 900,000 shares of common stock.
Silk Road Medical produces the Enroute transcarotid neuroprotection and stent system, which is intended for use during the transcarotid artery revascularization procedure, or TCAR.
“The Enroute system is part of the devic...
Source: Mass Device - April 4, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Vascular Wall Street Beat Silk Road Medical Inc. Source Type: news
